M
Monika E. Hegi
Researcher at University of Lausanne
Publications - 203
Citations - 36295
Monika E. Hegi is an academic researcher from University of Lausanne. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 72, co-authored 191 publications receiving 30374 citations. Previous affiliations of Monika E. Hegi include University Hospital of Lausanne & École Polytechnique Fédérale de Lausanne.
Papers
More filters
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp,Roger Stupp,Roger Stupp,Sophie Taillibert,Sophie Taillibert,Andrew A. Kanner,William L. Read,William L. Read,David M. Steinberg,Benoit Lhermitte,Steven A. Toms,Ahmed Idbaih,Manmeet Ahluwalia,Karen Fink,Francesco Di Meco,Frank S. Lieberman,Jay-Jiguang Zhu,Jay-Jiguang Zhu,Giuseppe Stragliotto,David Tran,Steven Brem,Steven Brem,Andreas F. Hottinger,Eilon D. Kirson,Gitit Lavy-Shahaf,Uri Weinberg,Chae-Yong Kim,Sun Ha Paek,Garth Nicholas,Jordi Burna,H Hirte,Michael Weller,Yoram Palti,Monika E. Hegi,Zvi Ram +34 more
TL;DR: In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance Temozolmide alone, resulted in statistically significant improvement in progression-free survival and overall survival.
Journal ArticleDOI
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmström,Bjørn Henning Grønberg,Christine Marosi,Roger Stupp,Didier Frappaz,Henrik Schultz,Ufuk Abacioglu,Björn Tavelin,Benoit Lhermitte,Monika E. Hegi,Johan Rosell,Roger Henriksson +11 more
TL;DR: A randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma found survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy and methylated and unmethylated MGMT promoter treated with radiotherapy.
Journal ArticleDOI
Maintenance therapy with tumor-Treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial
Roger Stupp,Roger Stupp,S. Taillibert,Andrew A. Kanner,Santosh Kesari,David M. Steinberg,Steven A. Toms,Lynne P. Taylor,Frank S. Lieberman,Antonio Silvani,Karen Fink,Gene H. Barnett,Jay-Jiguang Zhu,John W. Henson,Herbert H. Engelhard,Thomas C. Chen,David Tran,Jan Sroubek,Nam D. Tran,Andreas F. Hottinger,Joseph Landolfi,Rajiv D. Desai,Manuela Caroli,Yvonne Kew,Jérôme Honnorat,Ahmed Idbaih,Eilon D. Kirson,Uri Weinberg,Yoram Palti,Monika E. Hegi,Zvi Ram +30 more
TL;DR: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival.